Boston Institute of Biotechnology
Private Company
Funding information not available
Overview
Founded in 2012, Boston Institute of Biotechnology (BIB) has rapidly grown into a global CDMO with a focus on biologics and advanced therapies. Its key differentiators include claiming to house the world's first ultra-large 30,000L working volume bioreactor and a total biologics manufacturing capacity exceeding 200,000L, which it leverages to offer cost and timeline efficiencies. BIB operates on a service-based business model, generating revenue by providing process development, analytical services, and cGMP manufacturing to biotech and pharmaceutical partners.
Technology Platform
Full-service CDMO platforms for mammalian, microbial, and gene/cell therapy manufacturing, featuring proprietary ultra-large scale bioreactors (up to 50,000L), PanFlex-Engineering for facility solutions, and advanced Process Characterization methods.
Opportunities
Risk Factors
Competitive Landscape
BIB competes in a crowded global CDMO market against giants like Lonza, Catalent, and Samsung Biologics, as well as specialized gene therapy CDMOs. Its primary competitive claims are based on scale (world's largest bioreactors), speed (reducing timelines by 20-50%), and its integrated, de-risked service model.